← Back to Clinical Trials
Recruiting NCT06798181

NCT06798181 Neuropathic Pain and Type II Diabetic Patients

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06798181
Status Recruiting
Phase
Sponsor Bilecik Seyh Edebali Universitesi
Condition Neuropathic Pain
Study Type OBSERVATIONAL
Enrollment 128 participants
Start Date 2024-12-15
Primary Completion 2025-06-15

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 100 Years
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 128 participants in total. It began in 2024-12-15 with a primary completion date of 2025-06-15.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Diabetes Mellitus (DM) is a common metabolic disease characterized by hyperglycemia resulting from insufficiency, deficiency or absence of the insulin hormone. Chronic hyperglycemia, secondary metabolic and microvascular changes resulting in diabetic neuropathy are among the most common complications encountered in DM patients. Diabetic neuropathy is called peripheral, autonomic or spinal depending on the region of involvement. Peripheral involvement is more common than other region involvement and its prevalence in DM patients is observed to be 16-87%. Diabetic peripheral neuropathy (DPN) presents with numbness, tingling, paresthesia, muscle weakness and pain. These symptoms can start from the toes and progress to the leg and even the upper extremities. In diabetic peripheral neuropathy, pain is seen as burning, electric shock or sharp cold pain, increases at night and affects sleep quality. In these patients, daily living activities such as walking, climbing stairs, and sleeping are negatively affected by progressive DPN and pain, falls are observed, mood disorders are experienced, and the quality of life decreases.

Eligibility Criteria

Inclusion Criteria: * 18 years and older, * Diagnosed with type II diabetes, * Reading and writing, * No physical or psychological communication barriers, * Can read and speak Turkish, * Volunteers Exclusion Criteria: * Diagnosed with type I diabetes

Contact & Investigator

Central Contact

Burcu Bayrak Kahraman, PhD

✉ burcu.bayrak@bilecik.edu.tr

📞 +905057542411

Frequently Asked Questions

Who can join the NCT06798181 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 100 Years, studying Neuropathic Pain. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06798181 currently recruiting?

Yes, NCT06798181 is actively recruiting participants. Contact the research team at burcu.bayrak@bilecik.edu.tr for enrollment information.

Where is the NCT06798181 trial being conducted?

This trial is being conducted at Bilecik, Turkey (Türkiye).

Who is sponsoring the NCT06798181 clinical trial?

NCT06798181 is sponsored by Bilecik Seyh Edebali Universitesi. The trial plans to enroll 128 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology